Protalix BioTherapeutics reports stronger-than-expected Q2 earnings and revenue, driven by a 26.4% year-over-year increase.
Protalix BioTherapeutics reported Q2 GAAP earnings per share of $0.05, surpassing expectations by $0.06. Revenue reached $19.8 million, beating estimates by $6.87 million and rising 26.4% year-over-year.
The company’s cash reserves stood at $40.7 million as of June 30, 2026, providing liquidity for ongoing operations. Analysts had anticipated lower earnings and revenue figures for the quarter.
No immediate market reaction was disclosed in the release.